Enhanced Molecular Inversion Probes for NGS Target Enrichment
News Feb 04, 2014
Integrated DNA Technologies (IDT) will present its findings on the use of molecular inversion probes (MIPs) for next generation sequencing (NGS) target enrichment at the 15th annual Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, Feb 12-15.
John Havens PhD, Vice-President of Business Development at IDT, will talk about MIPs and their proven effectiveness in the enrichment of genomic content of biological samples for specific regions of interest. NGS can subsequently be used to characterize these regions at high coverage depths.
In comparison to other methods, MIPs provide high multiplexability of targets in a single tube, which combined with the ability to enrich small amounts of DNA, results in time- and cost-effective sequencing.
IDT has developed a procedure whereby a high-fidelity platform is used to synthesize MIPs as long as 200 bases, chemically phosphorylating them independent of sequence. The presence of full length MIPs is then verified using mass spectroscopy prior to pooling.
Barcodes can be directly incorporated via degenerate bases and used to characterize the complexity of target capture. Dr Havens will demonstrate the advantage of these MIPs in terms of target specificity and the capture of longer targets.
A direct comparison will also be given of this approach with hybridization for a set of oncology targets, highlighting the benefits of MIPs over more traditional methods.
Mechanism of ApoE4 Gene Toxicity in Alzheimer's Disease Neurodegeneration SolvedNews
ApoE4 exacerbates the brain damage caused by toxic tangles of Alzheimer's-associated protein, tau.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Synpromics Announces Gene Therapy Research Partnership with Solid BiosciencesNews
Synpromics partner with Solid Biosciences ro develop treatment options Duchenne muscular dystrophy.READ MORE